CCTG MA.33/BIG 3-07/TROG 07.01 – A Randomised Phase III Study of Radiation Doses and Fractionation Schedules for Ductal Carcinoma In Situ (DCIS) of the Breast

Time: Wednesday, December 9, 2020: 1:00 – 2:45 PM
Type: Oral Presentation
Session: General Session 2 (1:45 – 2:00 PM)
Abstract: A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)

Authors: Boon Hui Chua, Emma Link, Ian Kunkler, Ivo Olivotto, Antonia Helen Westenberg, Timothy Whelan, Guenther Gruber

Link: https://www.abstractsonline.com/pp8/#!/9223/presentation/580

CCTG MA.34/BIG 4-11 – A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer

Time: Wednesday, December 9, 2020: 8:00 AM
Type: Poster
Session: Poster Session 10 (8:00 AM)
Abstract: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial

Authors: Richard D. Gelber, Xin Victoria Wang, Bernard F. Cole, David Cameron, Fatima Cardoso, Vivianne Tjan-Heijnen, Ian Krop, Sherene Loi, Roberto Salgado, Astrid Kiermaier, Elizabeth Frank, Debora Fumagalli, Carmela Caballero, Evandro de Azambuja, Marion Procter, Emma Clark, Eleonora Restuccia, Sarah Heeson, Jose Bines, Sibylle Loibl, Martine Piccart-Gebhard

Link: https://www.abstractsonline.com/pp8/#!/9223/presentation/1334
CCTG MA.34/BIG 4-11 – A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as AdjuvantTherapy in Patients with Operable HER2-Positive Primary Breast Cancer

**Time**: Wednesday, December 9, 2020: 8:00 AM  
**Type**: Poster  
**Session**: Poster Session 7 (8:00 AM)  
**Abstract**: *Timelines to initiate an adjuvant phase III trial across the globe: A sub-analysis of the APHINITY trial*  
**Abstract #**: PS7-21  
**Authors**: Maria Alice Franzoi, Marion Procter, Orianne Emond, Damien Parlier, Noam Pondé, Daniel Eiger, Sebastien Guillaume, Linda Reaby, Christopher Twelves, Emma Clark, Evandro de Azambuja, Jose Bines  
**Link**: https://www.abstractsonline.com/pp8/#!/9223/presentation/1160

CCTG MA.34/BIG 4-11 – A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as AdjuvantTherapy in Patients with Operable HER2-Positive Primary Breast Cancer

**Time**: Wednesday, December 9, 2020: 6:30 – 7:45 PM  
**Type**: Poster  
**Session**: Spotlight Poster Discussion 3 (6:30 – 7:45 PM)  
**Abstract**: *BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial*  
**Abstract #**: PD3-01  
**Authors**: Ian Krop, Lorenza Mittempergher, Joseph Paulson, Fabrice Andre, Hervé Bonnefoi, Sherene Loi, Sibylle Loibl, Richard D Gelber, Carmela Caballero, Debora Fumagalli, Christa Dreezen, Rene Bernards, Laura van’t Veer, Martine Piccart  
**Link**: https://www.abstractsonline.com/pp8/#!/9223/presentation/792

CCTG MA.37/BIG 14-03 – PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

**Time**: Wednesday, December 9, 2020: 5:15 – 6:30 PM  
**Type**: Poster  
**Session**: Spotlight Poster Discussion 2 (5:15 – 6:30 PM)  
**Abstract**: *Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2- early breast cancer*  
**Abstract #**: PD2-03  
**Authors**: Erica L. Mayer, Christian Fesl, Amylou Dueck, Michael Gnant, Angela DeMichele, on behalf of the PALLAS study team  
**Link**: https://www.abstractsonline.com/pp8/#!/9223/presentation/783
Thursday, December 10, 2020

CCTG MAC.15/SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer

Time: Thursday, December 10, 2020: 9:00 – 11:30 AM
Type: Oral Presentation
Session: General Session 3 (9:00 – 11:30 AM)
Abstract: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)
Abstract #: G53-00
Authors: Kevin Kalinsky, William E Barlow, Funda Meric-Bernstam, Julie R Gralow, Kathy S Albain, Daniel Hayes, Nancy Lin, Edith A Perez, Lori J Goldstein, Stephen Chia, Subkhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martin, Miguel Gil Gil, Claudia Arce-Salinas, Etienne Brain, In Hae Park, Jean-Yves Pierga, Ana Hernandez Lluch, Manuel Ramos Vasquez, Manuel Ruiz Borrego, Kyung Hae Jung, Jean-Marc Ferrero, Anne Schott, Steve Shak, Priyanka Sharma, Danika L Lew, Jieling Miao, Debu Tripathy, Gabriel Hortobagyi, Lajos Pusztai

Link: https://www.abstractsonline.com/pp8/#!/9223/presentation/2794

Friday, December 11, 2020

CCTG MA.21 – A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel Versus Sequenced AC Followed by Paclitaxel Versus CEF as Therapy for Premenopausal Women and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer

Time: Friday, December 11, 2020: 3:30 – 4:45 PM
Type: Poster
Session: Spotlight Poster Discussion 12 (3:30 – 4:45 PM)
Abstract: Evaluation of sleep problems and their association with febrile neutropenia, leucopenia and infections in women receiving adjuvant chemotherapy for breast cancer in the Canadian Cancer Trials Group MA.21 trial
Abstract #: PD12-01
Authors: Audreylie Lemelin, Josée Savard, Michelle Chen, Margot Burnell, Mark N Levine, Lois Shepherd, Bingshu E Chen, Julie Lemieux

Link: https://www.abstractsonline.com/pp8/#!/9223/presentation/740